SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/49878"
 

Search: onr:"swepub:oai:gup.ub.gu.se/49878" > Tesaglitazar, a nov...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

Fagerberg, Björn, 1943 (author)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Wallenberglaboratoriet,Institute of Internal Medicine, Dept of Medicine,Wallenberg Laboratory
Edwards, S. (author)
Halmos, T. (author)
show more...
Lopatynski, J. (author)
Schuster, H. (author)
Stender, S. (author)
Stoa-Birketvedt, G. (author)
Tonstad, S. (author)
Halldorsdottir, S. (author)
Gause-Nilsson, Ingrid, 1957 (author)
show less...
 (creator_code:org_t)
2005-07-07
2005
English.
In: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 48:9, s. 1716-25
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • AIMS/HYPOTHESIS: Insulin resistance is associated with abnormalities in lipid and glucose metabolism, which are major components of metabolic syndrome and risk factors for vascular disease. This study examined the effect of tesaglitazar (Galida), a novel, dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, on lipid and glucose metabolism in patients with evidence of insulin resistance. METHODS: A 12-week, multicentre, randomised, double-blind, placebo-controlled, dose-finding study compared the efficacy and safety of oral tesaglitazar (0.1, 0.25, 0.5 and 1.0 mg/day) and placebo in 390 non-diabetic patients with hypertriglyceridaemia (plasma triglyceride concentration >1.7 mmol/l) and abdominal obesity (waist-to-hip ratio >0.90 for men and >0.85 for women). RESULTS: A 1.0-mg dose of tesaglitazar reduced fasting triglycerides (the primary endpoint) by 37% (95% CI: -43% to -30%; p<0.0001), non-HDL-cholesterol by 15% (95% CI: -20% to -10%; p<0.0001) and NEFA by 40% (95% CI: -51% to -27%; p<0.0001), and increased HDL-cholesterol by 16% (95% CI: 8 to -24%; p<0.0001). At the end of treatment there was a dose-dependent increase in patients with pattern A LDL particle diameter (40% at baseline vs 87% at 12 weeks for tesaglitazar 1.0 mg). Tesaglitazar produced significant reductions in fasting insulin concentration (-35%; p<0.0001) and plasma glucose concentration (-0.47 mmol/l; p<0.0001). Respiratory infection and gastrointestinal symptoms were the most common adverse events and were similarly frequent in all groups. CONCLUSIONS/INTERPRETATION: Tesaglitazar was well tolerated and produced significant, dose-dependent improvements in lipid and glucose metabolism and insulin sensitivity. Tesaglitazar may have the potential to prevent vascular complications and delay progression to diabetes in these patients.

Keyword

Alkanesulfonates/adverse effects/*therapeutic use
Blood Glucose/drug effects/*metabolism
Dose-Response Relationship
Drug
Double-Blind Method
Fatty Acids
Nonesterified/blood
Female
Humans
Insulin/blood
Lipids/blood
Male
Middle Aged
PPAR alpha/*antagonists & inhibitors
PPAR gamma/*antagonists & inhibitors
Phenylpropionates/adverse effects/*therapeutic use
Placebos
Safety
Triglycerides/blood

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view